Yıl: 2019 Cilt: 51 Sayı: 2 Sayfa Aralığı: 177 - 185 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2016.0237 İndeks Tarihi: 24-04-2020

Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer

Öz:
Objective: In this study, we investigated the frequency of Epidermal growth factor receptor (EGFR) gene mutations, the level of EGFR mRNA and protein expressions in Turkish population for indicating substantial differences in the frequency of EGFR mutations, EGFR amplification and EGFR protein expression between populations and the effect of these parameters in response to EGFR tyrosine kinase inhibitors.Materials and Methods: The study included 34 patients with non-small cell lung cancers. The RNA and DNA were extracted from the normal and tumor side of the lung tissue removed by surgery. To investigate the most common mutations in the EGFR gene, exon 19 was sequenced and mutation specific PCR was performed for detecting the L858R mutation in exon 21. EGFR mRNA expression was measured by relative quantitative reverse transcription PCR. The EGFR protein levels were detected with immunohistochemistry methods from the sections of the patients’ paraffin blocks.Results: No EGFR mutation in exon 19 or L858R mutation in exon 21 were detected in the patients. Overexpression of EGFR gene mRNA was identified in 16 of 34 (%47) patients and overexpression of EGFR protein was detected in 15 of 34 (%44) patients. Statistical analysis was not significant for the correlation between sex, age, smoking, histopathology, pathological stage and overexpression of EGFR mRNA and protein.Conclusion: It was found that in Turkish population, EGFR mutation in exon 19 and L858R mutation were very rare, EGFR protein expression was similar and EGFR mRNA expression significantly increased compared to the literature. Markedly increased EGFR mRNA expression ratios in the absence of activating mutations showed that identifying the EGFR mRNA expression level for prediction of response to EGFR tyrosine kinase inhibitors might be significant in the Turkish population.
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 1059-68. [CrossRef]
  • 2. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000; 18: 2354-62.
  • 3. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004; 10: 4227-32. [CrossRef]
  • 4. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 1103-9. [CrossRef]
  • 5. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6829-37. [CrossRef]
  • 6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500. [CrossRef]
  • 7. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643-55. [CrossRef]
  • 8. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005; 11: 5878-85. [CrossRef]
  • 9. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9. [CrossRef]
  • 10. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21: 3798-807. [CrossRef]
  • 11. Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2008; 134: 569-77. [CrossRef]
  • 12. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975-81. [CrossRef]
  • 13. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-44. [CrossRef]
  • 14. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91: 208-12. [CrossRef]
  • 15. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23: 857-65. [CrossRef]
  • 16. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46. [CrossRef]
  • 17. Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12: 4416-20. [CrossRef]
  • 18. http://www.ncbi.nlm.nih.gov/nuccore/188219609.
  • 19. Ni IBP, Lim P, Balraj P, Hang ESU, Zakaria Z. Quantitative analysis of the expression of p53 gene in colorectal carcinoma by using real-time PCR. Tropical Biomedicine. 2006; 23: 53-9.
  • 20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74. [CrossRef]
  • 21. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res. 2001;7:1850-5.
  • 22. Mafune K, Tanaka Y, Mimori K, Mori M, Takubo K, Makuuchi M. Increased expression of ornithine decarboxylase messenger RNA in human esophageal carcinoma. Clin Cancer Res. 1999;5:4073-8.
  • 23. Bong IP, Lim P, Balraj P, Sim Ui Hang E, Zakaria Z. Quantitative analysis of the expression of p53 gene in colorectal carcinoma by using real-time PCR. Trop Biomed. 2006;23:53-9.
  • 24. Gorgisen G, Ozes D, Pehlivanoglu S, et al. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC). Exp Lung Res. 2013;39:387-98. [CrossRef]
  • 25. Unal OU, Oztop I, Calibasi G, et al. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. Asian Pac J Cancer Prev. 2013;14:3705-9. [CrossRef]
  • 26. Akca H, Demiray A, Yaren A, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet. 2013;206:73-80. [CrossRef]
  • 27. Bircan S, Baloglu H, Kucukodaci Z, Bircan A. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study. Med Oncol. 2014;31:87. [CrossRef]
  • 28. Dogan M, Demirkazik A, Tukun A, et al. The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey. Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi. 2014;24:1-10. [CrossRef]
  • 29. Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol. 2010;27:853-60. [CrossRef]
  • 30. Al-Kuraya K, Siraj AK, Bavi P, et al. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol. 2006;37:453-7. [CrossRef]
  • 31. Sonobe M, Nakagawa M, Takenaka K, et al. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2007;95:63-9. [CrossRef]
  • 32. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res. 2008;14:3860-6. [CrossRef]
  • 33. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004;64:9139-43. [CrossRef]
  • 34. Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006;12:3078-84. [CrossRef]
  • 35. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006;125:860-5. [CrossRef]
  • 36. Seyhan EC, Altin S, Cetinkaya E, et al. Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma. Multidiscip Respir Med. 2010;5:305-11. [CrossRef]
  • 37. Gundogdu AG, Onder S, Firat P, Dogan R. EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases. Journal of Thoracic Disease. 2014;6:778-84.
  • 38. Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol. 2005;17:118-22. [CrossRef]
  • 39. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081-92. [CrossRef]
  • 40. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;16:1081-6. [CrossRef]
  • 41. Pinter F, Papay J, Almasi A, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn. 2008;10:160-8. [CrossRef]
  • 42. Qin BM, Chen X, Zhu JD, Pei DQ. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res. 2005;15:212-7. [CrossRef]
  • 43. Liang H, Zhang J, Shao C, et al. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 2012;31:36. [CrossRef]
  • 44. Sasaki H, Endo K, Takada M, et al. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer. 2006;54:103-8. [CrossRef]
  • 45. Suzuki M, Shigematsu H, Hiroshima K, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol. 2005;36:1127-34. [CrossRef]
  • 46. Yokoyama T, Kondo M, Goto Y, et al. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci. 2006;97:753-9. [CrossRef]
  • 47. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103:1265-73. [CrossRef]
  • 48. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10:8195-203. [CrossRef]
  • 49. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-501. [CrossRef]
APA TAŞDEMİR S, taheri s, Akalın H, KONTAŞ O, onal o, ÖZKUL Y (2019). Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. , 177 - 185. 10.5152/eurasianjmed.2016.0237
Chicago TAŞDEMİR Sener,taheri serpil,Akalın Hilal,KONTAŞ OLGUN,onal omer,ÖZKUL Yusuf Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. (2019): 177 - 185. 10.5152/eurasianjmed.2016.0237
MLA TAŞDEMİR Sener,taheri serpil,Akalın Hilal,KONTAŞ OLGUN,onal omer,ÖZKUL Yusuf Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. , 2019, ss.177 - 185. 10.5152/eurasianjmed.2016.0237
AMA TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. . 2019; 177 - 185. 10.5152/eurasianjmed.2016.0237
Vancouver TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. . 2019; 177 - 185. 10.5152/eurasianjmed.2016.0237
IEEE TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y "Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer." , ss.177 - 185, 2019. 10.5152/eurasianjmed.2016.0237
ISNAD TAŞDEMİR, Sener vd. "Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer". (2019), 177-185. https://doi.org/10.5152/eurasianjmed.2016.0237
APA TAŞDEMİR S, taheri s, Akalın H, KONTAŞ O, onal o, ÖZKUL Y (2019). Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine, 51(2), 177 - 185. 10.5152/eurasianjmed.2016.0237
Chicago TAŞDEMİR Sener,taheri serpil,Akalın Hilal,KONTAŞ OLGUN,onal omer,ÖZKUL Yusuf Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine 51, no.2 (2019): 177 - 185. 10.5152/eurasianjmed.2016.0237
MLA TAŞDEMİR Sener,taheri serpil,Akalın Hilal,KONTAŞ OLGUN,onal omer,ÖZKUL Yusuf Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine, vol.51, no.2, 2019, ss.177 - 185. 10.5152/eurasianjmed.2016.0237
AMA TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine. 2019; 51(2): 177 - 185. 10.5152/eurasianjmed.2016.0237
Vancouver TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine. 2019; 51(2): 177 - 185. 10.5152/eurasianjmed.2016.0237
IEEE TAŞDEMİR S,taheri s,Akalın H,KONTAŞ O,onal o,ÖZKUL Y "Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer." Eurasian Journal of Medicine, 51, ss.177 - 185, 2019. 10.5152/eurasianjmed.2016.0237
ISNAD TAŞDEMİR, Sener vd. "Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer". Eurasian Journal of Medicine 51/2 (2019), 177-185. https://doi.org/10.5152/eurasianjmed.2016.0237